Articles

What the five melanocortin receptors (MC1R–MC5R) do, the peptides that activate them, and why one non-selective agonist can tan skin or change desire.

What the gonadorelin label actually documents, why kisspeptin-10 has almost no human safety data, and why the side-effect tables circulating for it are invented.

Thymosin alpha-1 side effects per the Zadaxin label and randomized trials: well tolerated (under 1% drug-related AEs), plus what is not established and the real grey-market risk.

How the WADA Prohibited List captures research peptides through S0, S2 and S4 catch-alls, why strict liability applies, and why not being named is not protection.

Bacteriostatic water is generally good for about 28 days after first puncture. Here is where that beyond-use date comes from and how to handle an opened vial.

What agonist, partial agonist, antagonist and inverse agonist actually mean at a receptor, and why potency and efficacy are not the same thing.

Tachyphylaxis, tolerance, and downregulation are not synonyms: two describe how fast a response fades, one is the receptor-level mechanism behind it.

Injection site rotation is not just moving around a bit. The size of the area matters more than any other risk factor.

Oral peptide bioavailability is under 1% for a reason. Five gut barriers, and what oral semaglutide had to do to beat them.

What the evidence actually shows about longevity peptide side effects — and why the compounds with the least data look the safest.